Inovio Pharma (NASDAQ: INO) reported Q3 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.54 million versus the consensus estimate of $5.16 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.